Background: Mepolizumab and omalizumab are treatments for distinct but overlap-
| INTRODUC TI ON
Asthma is a heterogenous condition that affects approximately 235 million people worldwide.
1 Although most patients with asthma are able to manage their symptoms and enjoy a good quality of life, 5%-10% of patients suffer from severe asthma. 2 Severe asthma is associated with significant morbidity and mortality, 3 and accounts for approximately 50% of asthma care costs. 4 Patients with severe asthma typically require regular treatment with high-dose inhaled corticosteroids (ICS), plus an additional controller or systemic corticosteroids (SCS) to prevent their disease from becoming uncontrolled. 2 Despite this therapy, a subset of patients continue to have uncontrolled disease.
Severe asthma comprises different phenotypes driven by distinct pathophysiological processes. 5 However, some severe asthma phenotypes overlap in terms of clinical and physiological characteristics, biomarker expression, and treatment response. 2, 5 In clinical practice, severe allergic asthma and severe eosinophilic asthma are recognized as distinct, but potentially overlapping phenotypes of severe asthma. 6 Severe allergic asthma is characterized by an early age of onset, high levels of serum immunoglobulin E (IgE), high fractional exhaled nitric oxide (FeNO), clinically relevant sensitization to common aeroallergens and eosinophilic inflammation; severe eosinophilic asthma is characterized by a later age of onset, peripheral eosinophilia, high FeNO, and frequent exacerbations. 2, 5 Due to the unmet clinical need within these severe asthma populations, novel biologic therapies that target the immunologic mediators of disease have been developed. 4 Omalizumab is an anti-IgE antibody indicated for use in patients with moderate-to-severe allergic asthma. 7 The humanized monoclonal antibody binds to the FcεRI binding domain of free circulating IgE, inhibits binding of IgE to its receptors, and decreases free IgE levels in serum. 8 In patients with severe asthma, omalizumab treatment decreases exacerbations, improves asthma control and improves patient quality of life. [9] [10] [11] Omalizumab is recommended by the Global Initiative for Asthma (GINA) as a potential
Step 5 treatment for patients with severe allergic asthma. 12 However, in some patients, symptoms remain Conclusion: After directly switching from omalizumab to mepolizumab, patients with uncontrolled severe eosinophilic asthma experienced clinically significant improvements in asthma control, health status, and exacerbation rate, with no tolerability issues reported.
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G R A P H I C A L A B S T R A C T
Minimal clinically important difference for improvement in asthma control questionnaire-5 and St. George's Respiratory Questionnaire total scores was achieved by 77% and 79% of patients, respectively. Annualized rate of clinically significant exacerbations was reduced from 3.26 to 1.18 events/year. Safety and immunogenicity profiles of mepolizumab were consistent with previous placebo-controlled trials in severe eosinophilic asthma.
uncontrolled despite omalizumab therapy. The European Respiratory Society/American Thoracic Society guidelines note that if symptoms do not improve within 4 months of initiating omalizumab treatment, further administration is unlikely to be beneficial.
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Mepolizumab is an anti-interleukin (IL)-5 humanized monoclonal antibody indicated for use in severe eosinophilic asthma. 13 By binding with high affinity to free IL-5, mepolizumab blocks the interaction between IL-5 and the eosinophil cell surface receptor IL5Rα, preventing IL-5-driven eosinophil proliferation, survival and differentiation. 14 Mepolizumab effectively decreases peripheral blood eosinophil counts and exacerbations, [15] [16] [17] reduces oral glucocorticoid dependence, 15 and improves lung function and health-related quality of life in patients with severe eosinophilic asthma. 16, 18 Mepolizumab is also recommended by GINA as a potential Step 5 treatment for patients with severe eosinophilic asthma.
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Omalizumab has been available for clinical use since 2003. 7 As such, some patients with severe asthma who are eligible for both biologics have been receiving omalizumab. 18, 19 The primary objective of this study was to identify patients with severe eosinophilic asthma being treated with omalizumab whose disease was not optimally controlled, and to evaluate, in a pragmatic setting, any improvement in asthma control following a switch from omalizumab to mepolizumab without a washout period.
| ME THODS

| Study design and treatment
OSMO (Omalizumab Switch to MepOlizumab study) was an open-label, single-arm, multicenter trial in patients with severe eosinophilic asthma not optimally controlled by omalizumab treatment (NCT02654145).
Details of study locations are provided in the Appendix S1. The single-arm study design was chosen in order to focus on the switch from omalizumab to mepolizumab in a manner that reflects clinical practice.
Following a prescreening phase, which occurred over a 2-week period, patients attended a screening visit (Visit 1) to assess eligibility for the study. Eligible patients entered a 1-4 weeks run-in period, during which their continued eligibility was assessed. All maintenance therapy, including omalizumab, was continued throughout the run-in period. At the baseline study visit (Visit 2), patients discontinued omalizumab treatment and switched to mepolizumab 100 mg subcutaneously every 4 weeks for 32 weeks (final dose Week 28). With the exception of omalizumab, patients continued their maintenance therapies in unchanged dosages throughout the study period.
| Patients
Eligible patients were ≥12 years of age (or ≥18 years of age where local regulations restricted enrollment to adults), had a physician's diagnosis of asthma for ≥2 years according to National Heart, Lung 
| Endpoints and assessments
The primary endpoint was mean change from baseline at Week 32 in ACQ-5 score. The ACQ-5 score has a range of 0-6 with higher scores indicating worse asthma control. The minimum clinically important difference (MCID) in ACQ-5 score has been established as 0.5 points.
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Secondary endpoints were mean change from baseline at Week 32
in St George's Respiratory Questionnaire (SGRQ) score, frequency of clinically significant asthma exacerbations over the 32-week study period (Appendix S1), and ratio to baseline at Week 32 of blood eosinophil count. SGRQ scores range from 0 to 100, with higher scores indicating worse health status (MCID = 4-point change in score). 23 Additional endpoints included the percentage of patients achieving ≥0.5-point reduction from baseline in ACQ-5 score, the percentage of patients achieving ≥4-point reduction from baseline in SGRQ total score, and mean change from baseline in pre-and postbronchodilator FEV 1 , all at Week 32. We also assessed the frequency of exacerbations requiring an emergency room (ER) visit or hospitalization over the 32-week study period, patient-and clinician-rated response to therapy, and the mean change from baseline in Treatment Satisfaction Questionnaire for Medication (TSQM-9). The TSQM-9
Overall Satisfaction Scale score has a range of 0-100, with higher scores indicating greater satisfaction. Levels of inflammatory biomarkers were also assessed (Appendix S1).
Safety endpoints were the frequency of adverse events (AEs), serious AEs (SAEs) and AEs of special interest (AESIs; Appendix S1).
AEs were recorded on a worksheet by patients and documented by study staff at each visit. 
| Statistical analysis
The intent-to-treat (ITT) population, defined as all patients who were enrolled in the study and received ≥1 dose of mepolizumab, formed the primary analysis population. To take into account a possible "placebo effect" or "Hawthorne effect" due to clinical trial participation, the primary endpoint data were also compared to two "historical placebo" estimates produced from meta-analyses of previous studies of mepolizumab in patients with severe eosinophilic asthma.
The first, a meta-analysis of DREAM (NCT01000506) 17 and MENSA (NCT01691521) 16 using all placebo patients, estimated a "placebo effect" of −0.55 mean change from baseline in ACQ-5 score (standard error [SE]: 0.05); and the second, a meta-analysis of MENSA and MUSCA (NCT02281318) 18 using placebo patients previously treated with omalizumab, estimated a "placebo effect" of −0.11 mean change from baseline in ACQ-5 score (SE: 0.14).
We estimated that a sample size of 120 would provide 90%
power to declare statistical significance over the historical "placebo effect" of −0.55 mean improvement from baseline in ACQ-5 score at a two-sided significance level of 5%. These estimates were made based on a residual standard deviation (SD) of 0.96 and assumed 15% of patients would withdraw from the study prematurely.
Comparisons in all efficacy endpoints were made back to baseline. Questionnaires, blood eosinophil counts, and lung function tests were analyzed using a mixed model repeated measures model (MMRM) with covariates of region, baseline maintenance OCS therapy (OCS, no OCS), exacerbations in the prior year, and visit. For ACQ-5, the primary comparison was based on estimates from week 32. Exacerbation data were analyzed using a generalized estimating equation (GEE) model 24 assuming a negative binomial distribution with a covariate of treatment period (pretreatment, 32 weeks study period). For blood eosinophil counts, where a result of zero was recorded, a small value (ie, half the minimum nonzero result) was imputed prior to log-transformation.
Post hoc subgroup analyses were additionally conducted in patients who were or were not receiving maintenance OCS at baseline, and in patients who experienced ≥2 exacerbations during the ontreatment period. All statistical analyses were performed using SAS version 9.4 (SAS Institute).
F I G U R E 1 Overview of study design and patient flow. One patient failed two inclusion/exclusion criteria at screening *Fourteen patients (10%) received mepolizumab and were included in the ITT population despite having failed ≥ 1 eligibility criterion, see Table S1 for details. There were two patients that discontinued treatment with mepolizumab due to adverse events (urticaria and ECG QT prolonged) but who were not withdrawn and completed the study. ECG, electrocardiogram; ITT, intent-to-treat Overall, 206 patients currently receiving omalizumab were enrolled in the study, of whom 145 were switched to mepolizumab and were included in the ITT population. Seven patients (5%) withdrew from the study and two additional patients (1%) withdrew from the investigational product (mepolizumab) due to AEs but completed the study (Figure 1 ). Demographic and baseline clinical characteristics are summarized in Table 1 . Patients in the ITT population had an average age of 53.6 years and 59% were women. Overall, 52% and 48% of patients previously received omalizumab every 2 weeks and every 4 weeks, respectively, with a median (range) prior omalizumab treatment duration of 29.6 (4, 161) months (Table 1) .
| Primary endpoint
Patient ACQ-5 scores improved substantially over the study period, 
| Secondary endpoints
The LS mean (SE) SGRQ total score improved from 56.7 (1.36) at baseline to 37.8 (1.78) at Week 32, giving an LS mean change (SE) of Sixty patients (41%) experienced a total of 104 clinically significant exacerbations during the 32-week study period, of whom 15 patients required an ER visit/hospitalization and 9 patients required hospitalization. During the study period, the annualized rates of clinically significant exacerbations and exacerbations requiring an ER visit/hospitalization were reduced by 64% and 69%, respectively, compared with the year prior to study enrollment ( Table 2 ). The cumulative incidence for time to first clinically significant exacerbation is shown in Figure S1 .
In the subgroup of patients who experienced ≥2 exacerbations during the on-treatment period (n = 24), the mean (SD) number of exacerbations during the 12 months prior to screening was 4.3 (3.61) compared with 3.3 (2.65) in the overall study population. Other disease characteristics were similar to those in the overall ITT population (Table S2) . Despite experiencing ≥2 exacerbations during mepolizumab treatment, 6/24 (25%) patients in this subgroup still experienced a ≥10% reduction in exacerbation rate while on treatment compared with the 12 months prior to the study (Table S3 ).
As observed in previous studies, blood eosinophil counts de- 
| Additional endpoints
Prebronchodilator In subgroup analyses, improvements from baseline were seen in ACQ-5 score, SGRQ total score, and prebronchodilator FEV 1 at Week 32 both in patients who required maintenance OCS use at baseline and in those who did not (Table S4) . Additionally, compared with the year prior to study enrollment, the annualized rate of clinically significant exacerbations was reduced during the study period by 51% in patients who required maintenance OCS use at baseline and by 69% in patients who did not (Table S4 ).
| Safety
Overall, 124 patients (86%) experienced an on-treatment AE ( Table 3 ).
The most frequently reported AEs were headache (28%) and viral upper respiratory tract infection (17%). Sixteen patients (11%) experienced an on-treatment SAE, of whom 7 (5%) experienced asthma worsening. These seven patients did not display any common clinical characteristics, and all tested negative for ADAs. Overall, AEs were comparable in the first 16 weeks of the study, when omalizumab was within the patients' system, and in the second 16 weeks of the study, when omalizumab is anticipated to have washed out (data not shown).
Two patients (1%) experienced AEs that led to permanent treatment discontinuation: one patient reported a nonserious AE of worsening urticaria and subsequently re-started omalizumab (which is indicated for the treatment of urticaria 7 ); a second patient met the protocol defined ECG stopping criteria with nonserious AE of prolonged ECG QT. Neither AE was considered related to mepolizumab treatment by the investigator. Both patients discontinued treatment but remained within the study until completion.
No events of anaphylaxis were reported. One systemic hypersensitivity reaction was reported, which was described as a symptom of headache; this occurred in a patient 35 days after the first dose, and 4 days after the last dose, of mepolizumab. The reaction was assessed as mild and nonserious by the investigator and resolved with continued mepolizumab treatment. Five (3%) patients experienced local injection site reactions. All AESIs are summarized in Table 3 .
TA 
TA B L E 1 (Continued)
At any time, postbaseline, eleven patients (8%) tested positive for ADAs, of whom one patient tested ADA-positive prior to commencing mepolizumab treatment. All patients tested negative for neutralizing antibodies postbaseline.
| D ISCUSS I ON
Patients with severe eosinophilic asthma not optimally controlled by omalizumab experienced a clinically significant benefit in asthma control following a direct switch from omalizumab to mepolizumab.
Over the study period, the adjusted LS mean change in ACQ-5 score was substantially greater than the MCID of 0.5 points, demonstrat- Despite switching patients from one biologic to another without a washout period, the safety and immunogenicity profiles of mepolizumab during this study were similar to previous clinical trials in patients with severe eosinophilic asthma.
28
Omalizumab has previously been reported to reduce peripheral blood eosinophil counts in patients with severe asthma, 29 and to have greater efficacy in terms of exacerbation reduction in patients with blood eosinophil counts ≥260 cells/µL 30 or ≥300 cells/µL, 31, 32 as compared with patients with lower blood eosinophil counts.
Interestingly, the present study assessed patients whose asthma glucocorticoid-based therapies. [33] [34] [35] It is possible that patients in the ITT population were experiencing obesity-related asthma, which may have contributed to the severity of their disease and lack of response to standard of care therapies. Notwithstanding, the majority (77%) of patients in the ITT population experienced a clinically significant improvement in asthma control in response to mepolizumab.
The principal limitation of this study was the single-arm design without a randomized control group. This limitation was partly addressed using historical placebo control estimates, generated by metaanalyses of previous clinical trials of mepolizumab in patients with severe eosinophilic asthma. The clinical trials used in these meta-analyses were of similar length and had comparable inclusion and exclusion criteria; therefore, the "placebo estimates" were based on patients of similar clinical status and disposition. In particular, the meta-analysis of MENSA/MUSCA only included patients who had previously received omalizumab therapy. Secondly, this was a 32-week, rather than 12-month study. Thirty-two weeks is shorter than the ideal time frame for assessment of exacerbation rates; however, this limitation was partly mitigated through recruitment of patients across seasons, reducing seasonality confounding. Furthermore, although clinical conditions may vary when comparing exacerbation rates pre-and poststudy, objective measures such as FEV 1 and blood eosinophil counts showed the same trend as exacerbation rates over this time frame. Thirdly, as patients were receiving omalizumab treatment prior to entering the study, the initial indications for prescribing omalizumab were not known for all patients, and therefore could have been incorrect in a subset. Nonetheless, it is thought that these patients were likely to have been identified as suitable for omalizumab treatment according to the product label and, as such, would have been diagnosed with allergic asthma and received the appropriate dose of omalizumab based on their IgE levels. Indeed, one of the study inclusion criteria stated that study patients must have been receiving omalizumab based on weight and IgE levels. As patients were not required to washout prior to the switch to mepolizumab, baseline measurements of atopy were not collected as these would have been confounded by current omalizumab treatment. Finally, to justify the study treatment, this study was conducted in a subgroup of patients eligible for both omalizumab and mepolizumab who had uncontrolled disease. Consequently, the results of this study are not necessarily generalizable to the entire overlapping population of patients eligible for both biologics. Abbreviations: AE, adverse event; AESI, adverse event of special interest; ECG, electrocardiogram; ITT, intent-to-treat; SAE, serious adverse event; SC, subcutaneous. Data are presented as n (%). a On-treatment refers to the time between the first dose of mepolizumab and 4 wk after the last dose of mepolizumab. form of writing assistance, including development of the initial draft from the study report, assembling tables and figures, collating authors comments, grammatical editing and referencing) was provided by Natasha Dean, MSc, and Susan Parker, PhD, at Fishawack Indicia Ltd, UK, and was funded by Glaxo Smith Kline (GSK). 
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